Hypoallergenic derivatives of major grass pollen allergens for allergy vaccination

Immunology and Cell Biology

Volumn 81, Issue 1, 2003, Pages 86-91

  Singh, Mohan B ^a   Bhalla, Prem L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Grass pollen allergy; Hay fever; Hypoallergen; IgE; Immunotherapy; Recombinant allergen; Type 1 allergy

Indexed keywords

POLLEN ANTIGEN;

ALLERGENICITY; ALLERGIC ASTHMA; ALLERGY; HAY FEVER; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOTHERAPY; INDUSTRIALIZATION; MOLECULAR BIOLOGY; REVIEW;

ALLERGENS; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; PHLEUM; POACEAE; POLLEN; VACCINES;

SECALE CEREALE;

EID: 0037329809     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0818-9641.2002.01144.x     Document Type: Review

References (58)

1. Cookson WO, Moffatt MF. Alchemy for asthma. Nat. Med. 1998; 4: 500-1.
2. Miyamoto T. Advances in Allergology and Clinical Immunology. In: Godard P, Bousquet J, Michel FB (eds). Comforth, UK: The Parthenon Publishing Group, 1992; 343-7.
3. Burney P, Bousquet J. Evidence for an increase in atopic disease and possible cause. Clin. Exp. Allergy 1993; 23: 484-92.
4. Bieber T. Fc epsilon R1 on antigen presenting cells. Curr. Opin. Immunol. 1996; 8: 773-7.
5. Stingl G, Maurer D. IgE-mediated allergen presentation via Fc epsilon R1 on antigen presenting cells. International Arch. Allergy Immunol. 1997; 113: 24-9.
6. Freidhoff LR, Ehrlich-Kautzky E, Grant JH, Meyers DA, Marsh DG. A study of the human immune response to Lolium perenne (rye) pollen and its components, Lol, p. I and Lol, p. II (rye I and rye II). I. Prevalence of reactivity to the allergens and correlations among skin test, IgE antibody, and 1gG antibody data. J. Allergy Clin. Immunol. 1986; 78: 1190-201.
7. Baldo BA, Sutton R, Wrigley CW. Grass allergens, with particular reference to cereals. Prog. Allergy 1982; 30: 1-66.
8. Martin BG, Mansfield LE, Nelson HS. Cross-allergenicity among the grasses Ann. Allergy. 1985; 54: 99-104.
9. Schumacher MJ, Grabowski J, Wagner CM. Anti-Bermuda grass RAST binding is minimally inhibited by pollen extracts from ten other grasses. Ann. Allergy 1985; 55: 584-7.
10. Ford SA, Baldo BA. A re-examination of ryegrass (Lolium perenne) pollen allergens. Int. Arch. Allergy Appl. Immunol. 1986; 81: 193-203.
11. Griffith IJ, Smith PM, Pollock J et al. Cloning and sequencing of Lol, p I, the major allergenic protein of rye-grass pollen. FEBS Lett. 1991; 279: 210-15.
12. Singh MB, Hough T, Theerakulpisut P et al. Isolation of cDNA encoding newly identified major allergenic protein of rye-grass pollen: intracellular targeting to the amyloplast. Proc. Natl Acad. Sci. USA 1991; 88: 1384-8.
13. de Weerd Bhalla PL, Singh MB. Aeroallergens and polliniosis: Molecular and immunological characteristics of cloned pollen allergens. Aerobiologia 2002; 18: 87-106.
14. Shcherban TY, Shi J, Durachko DM et al. Molecular cloning and sequence analysis of expansins - a highly conserved, multigene family of proteins that mediate cell wall extension in plants. Proc. Natl Acad. Sci. USA 1995; 92: 9245-9.
15. Cosgrove DJ, Bedinger P, Durachko DM. Group I allergens of grass pollen as cell wall-loosening agents. Proc. Natl Acad. Sci. USA 1997; 94: 6559-64.
16. Grobe K, Becker WM, Schlaak M, Petersen A. Grass group I allergens (beta-expansins) are novel, papain-related proteinases. Eur. J. Biochem. 1999; 263: 33-40.
17. Grobe K, Poppelmann M, Becker WM, Petersen A. Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of cysteine proteinases. Eur. J. Biochem. 2002; 269: 2083-92.
18. Vrtala S, Sperr WR, Reimitzer I et al. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Ph1, p 5 allergen. J. Immunol. 1993; 151: 4773-81.
19. Bhalla PL, Swoboda I, Singh MB. Antisense-mediated silencing of a gene encoding a major ryegrass pollen allergen. Proc. Natl Acad. Sci. USA 1999; 96: 11676-80.
20. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergenic drugs. BMJ 1991; 302: 265-9.
21. Platts-Mills TAE, Mueller GA, Wheatley LM. Future directions for allergen immunotherapy. J. Allergy Clin. Immunol. 1998; 102: 335-43.
22. Rolland JM, Douglass J, O'Hehir RE. Allergen immunotherapy: current and new therapeutic strategies. Expert Opin. Investig. Drugs 2000; 9: 515-27.
23. Rolland JM, O'Hehir RE. Allergen immunotherapy: current and new therapeutic strategies. Allergol. Int. 2002; 51: 221-31.
24. Bosquet J, Lockey R, Malling HJ. Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases. A WHO position paper Allergy 1998; 53: 1-42.
25. Secrist H, DeKruyff RH, Umetsu DT. Interleukin 4 production by CD4+ cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J. Exp. Med. 1995; 181: 1081-90.
26. Durham SR, Ying S, Varney VA et al. Grass pollen immuno-therapy inhibits allergen induced infiltration of of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon gamma. J. Allergy Clin. Immunol. 1996; 97: 1356-65.
27. Bosquet J, Becker WM, Hejjoi A et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. J Allergy Clin. Immunol. 1991; 88: 43-53.
28. Focke M, Mahler V, Ball T et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 2001; 15: 2042-4.
29. van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation J. Immunol. 1999: 163: 2944-52.
30. van Neerven RJJ, Ebner C, Yssel H, Kapsenberg ML, Lamb JR. T cell responses to allergens: epitope specificity and clinical relevance Immunol. Today 1996; 17: 526-32.
31. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. 1996; 8: 1937-45.
32. Muller U, Adkis A, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phosphplipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 1998; 101: 747-57.
33. O'Brien RM, Thomas WR, Nicholson I, Lamb JR, Tait BD. An immunogenetic analysis of the T-cell recognition of the major house dust mite allergen Der, p 2: identification of high- and low-responder HLA-DQ alleles and localization of T-cell epitopes: Immunology 1995; 86: 176-82.
34. Marsh DG, Lichtenstein LM, Campbell DH. Studies on 'allergoids' prepared from naturally occuring allergens. I. Assay of allergenicity and antigenicity of formalinized rye grass I component. Immunology 1970: 18: 705-22.
35. Marsh DG. Preparation and properties of allergoids, derived from native pollen allergens by mild formalin treatment. Int. Arch. Allergy Immunol. 1971; 41: 199-215.
36. Grammer LC, Shaughnessy MA, Paterson R. Modified forms of allergen immunotherapy. J. Allergy Clin. Immunol. 1985; 76: 397-401.
37. Hayglass KT, Stefura WP. Anti-IFN gamma treatment blocks the ability of polymerized allergens to inhibit specific IgE responses. J. Exp. Med. 1991; 173: 279-87.
38. Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occuring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J. Allergy Clin. Immunol. 1981; 68: 460-70.
39. Kraft D, Ferreira F, Ebner C et al. Recombinant allergens: the future of the diagnosis and treatment of atopic allergy. Allergy 1998; 53: 62-6.
40. Chapman MD, Smith AM, Vailes LD, Pomes A. Recombinant allergens for immunotherapy. Allergy Asthma Proc. 2002; 23: 5-8.
41. Singh MB, deWeerd N, Bhalla PL. Genetically engineered plant allergens with reduced anaphylactic activity. Int. Arch. Allergy Immunol. 1999; 119: 75-85.
42. Valenta R, Vrtala S. Recombinant allergens for specific immunotherapy Allergy 1999; 56: 43-4.
43. Ferreira F, Hirtenlehner K, Jilek A, Godnik-Cvar J, Breiteneder H et al. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v, 1. Potential use of hypoallergenic isoforms for immunotherapy. J. Exp. Med. 1996; 183: 599-609.
44. Gehlhar K, Petersen A, Schramm G, Becker WM, Schlaak M, Bufe A. Investigation of different recombinant isoforms of grass group-V allergens (timothy grass pollen) isolated by low-stringency cDNA hybridization - antibody binding capacity and allergenic activity. Eur. J. Biochem. 1997; 247: 217-23.
45. Chang Z-N, Peng H-J, Lee WC et al. Sequence polymorphism of the group 1 allergen of Bermuda grass pollen. Clin. Exp. Allergy' 1999; 29: 488-96.
46. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis, contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der, p 2. Mol. Immunol. 1996; 33: 399-405.
47. Takai T, Yokota T, Yasue M et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immuno-therapy. Nat. Biotechnol. 1997; 15: 754-8.
48. de Weerd N, Bhalla PL, Singh MB. Effect of cysteine mutagenesis on human IgE reactivity to a recombinant form of the major rye grass pollen allergen Lol, p 1. Allergol. Int. (submitted).
49. Ansari AA, Shenbagamurthi P, Marsh DG. Complete primary structure of a Lolium perenne (perennial rye grass) pollen allergen, Lol, p. III. comparison with known Lol, p. I and II sequences. Biochemistry 1989; 28: 8665-70.
50. Esch RE, Klapper DG. Isolation and characterization of a major cross-reactive grass group I allergenic determinant. Mol. Immunol. 1989; 26: 557-61.
51. Van Ree R, van Leeuwen WA, van den Berg M, Weller HH, Aalberse RC. IgE and IgG cross-reactivity among Lol p I and Lol p II/III. Identification of the C-termini of Lol p I, II, and III as cross-reactive structures. Allergy 1994; 49: 254-61.
52. Lamontagne P, Boutin Y, Brunet C, Boulanger J, Berton J, Hebert J. Characterization of allergenic determinants on the C-terminal region of the r-Lol, p 1. Adv. Exp. Med. Biol. 1996; 409: 425-9.
53. Tamborini E, Faccini S, Lidholm J et al. Biochemical and immunological characterization of recombinant allergen Lol, p 1. Eur. J. Biochem. 1997; 249: 886-94.
54. Schramm G, Kahlert H, Suck R et al. 'Allergen engineering': variants of the timothy grass pollen allergen Ph1, p 5 with reduced IgE-binding capacity but conserved T cell reactivity. J. Immunol. 1999; 162: 2406-14.
55. Swoboda I, de Weerd N, Bhalla PL et al. Mutants of the major ryegrass pollen allergen, Lol, p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur. J. Immunol. 2002; 32: 270-80.
56. Ong EK, Knox RB, Singh MB. Mapping of the antigenic epitopes of Lol, p. VB using gene fragmentation. Mol. Immunol. 1995; 32: 295-302.
57. Suphioglu C, Blaher B, Rolland JM et al. Molecular basis of IgE-recognition of Lol, p 5, a major allergen of rye-grass pollen. Mol. Immunol. 1998; 35: 293-305.
58. Hiller R, Laffer S, Harwanegg C et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J. 2002; 16: 414-16.